Page last updated: 2024-12-07

3,4,5-tri-o-galloylquinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4,5-tri-O-galloylquinic acid: DNA polymerase inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127406
CHEMBL ID310527
SCHEMBL ID21191607
SCHEMBL ID21176638
MeSH IDM0171758

Synonyms (17)

Synonym
3,4,5-gqa
CHEMBL310527 ,
NSC692283 ,
tgqa
3,4,5-tri-o-galloylquinic acid
(3r,5r)-1-hydroxy-3,4,5-tris[(3,4,5-trihydroxybenzoyl)oxy]cyclohexanecarboxylic acid
benzoic acid, 3,4,5-trihydroxy-, (1r,2a,3r,5a)-5-carboxy-5-hydroxy-1,2,3-cyclohexanetriyl ester, rel-
(3r,5r)-1-hydroxy-3,4,5-tris(3,4,5-trihydroxyphenylcarbonyloxy)cyclohexanecarboxylic acid
99745-62-7
3,5-tri-o-galloylquinic acid
nsc-692283
benzoic acid, 3,4,5-trihydroxy-, 5-carboxy-5-hydroxy-1,2,3-cyclohexanetriyl ester, (1alpha,3alpha,4alpha,5beta)-
DTXSID40912512
SCHEMBL21191607
Q10859487
SCHEMBL21176638
bdbm50469576
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID358165Cytotoxicity against human PRMI7951 cells by tetrazolium salt-based colorimetric assay1992Journal of natural products, Aug, Volume: 55, Issue:8
Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents.
AID358166Cytotoxicity against human KB cells by tetrazolium salt-based colorimetric assay1992Journal of natural products, Aug, Volume: 55, Issue:8
Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents.
AID358167Cytotoxicity against human A549 cells by tetrazolium salt-based colorimetric assay1992Journal of natural products, Aug, Volume: 55, Issue:8
Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents.
AID335227Inhibition of HIV reverse transcriptase assessed as incorporation of [3H]dTMP at 30 uM
AID335234Cytotoxicity against human H9 cells at 25 uM
AID358169Cytotoxicity against human TE671 cells by tetrazolium salt-based colorimetric assay1992Journal of natural products, Aug, Volume: 55, Issue:8
Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents.
AID335228Inhibition of HIV reverse transcriptase assessed as incorporation of [3H]dTMP at 10 uM
AID335235Cytotoxicity against human H9 cells at 1.25 uM
AID335233Antiviral activity against HIV1 3B replication in human H9 cells at 7.7 uM after 3 days by p24 antigen capture assay relative to control
AID334988Inhibition of HIV reverse transcriptase assessed as incorporation of [3H]dTMP at 100 uM
AID358168Cytotoxicity against human HCT8 cells by tetrazolium salt-based colorimetric assay1992Journal of natural products, Aug, Volume: 55, Issue:8
Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents.
AID335236Cytotoxicity against human H9 cells at 6.25 uM
AID335237Antiviral activity against HIV1 3B replication in human H9 cells at 1.5 uM after 3 days by p24 antigen capture assay relative to control
AID335232Antiviral activity against HIV1 3B replication in human H9 cells at 30.8 uM after 3 days by p24 antigen capture assay relative to control
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]